Abstract: The present invention relates to a process for producing a chitosan-containing soft capsule. The process includes the steps of rendering chitosan a powder; adding the chitosan powder, powder comprising an organic acid and a salt thereof, and an emulsifier to an oil or fat; stirring the resultant mixture so as to suspend the powders, to thereby obtain a gel-like stock; and feeding the gel-like stock and a gelatin solution for coating into an automated encapsulation machine, to effect encapsulation of the stock with gelatin.

Abstract: A medicament for nasal administration to be used for disease prevention or treatment comprising a vaccine or a pharmacologically active peptide compounded with an ion exchange resin or adsorbent resin powder whose mean particle size is not larger than 200 .mu.m.

Abstract: Sugar-modified interferon, modified with at least one galactose residue, which is a binding reaction product between lactose lactone and interferon is disclosed. The sugar-modified interferon, which can be obtained through simple chemical manipulation on IFN, has improved accumulating properties in the liver and enhanced physiological activities as compared with unmodified IFN.

Abstract: A pharmaceutical composition effective for the therapy of cerebral thrombosis, particularly acute cerebral thrombosis, which is in the form of a fat emulsion containing an isocarbacyclin having a specific structure, and a method for the therapy of cerebral thrombosis.

Abstract: An osteogenesis promoter and/or osteoporosis remedy comprising, as an active ingredient, an androgen derivative represented by the following formula (1): ##STR1## wherein each broken line indicates that the relevant carbon-to-carbon bond is a single bond or a double bond or a salt thereof. The compound (1) activates osteoblasts, promotes osteogenesis and increases the bone mass, so that it is used for the treatment of a morbid condition of lowered osteogenesis due to aging, immobilization, administration of glucocorticoids and so forth. Further, it can increase the bone mass by its osteogenesis promoting effect so that it is useful for the treatment of osteoporosis accompanying the above morbid condition or occurring after ovariectony or menopause.

Abstract: A topical preparation containing cyclosporin as an active ingredient, is disclosed that contains (a) cyclosporin; (b) an organic solvent for dissolving the cyclosporin; (c) an ester of a fatty acid with a monovalent alcohol having a total number of carbon atoms of 8 or more and/or an alkanol amine, each being in liquid state at 25.degree.C; (d) an oily substance in solid state at 25.degree.C; and (e) a surfactant. The cyclosporin is present in a concentration ranging from appoximately 0.1% to 10% by weight and the ester and/or alkanol amine are/is present in a concentration ranging from approximately 1% to 15% by weight. The topical preparations are active against atopic dermatitis, psoriasis and allergic contact dermatitis.

Abstract: A composition which comprises a modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linkage and a protein inhibitor which does not inhibit the modified biologically active protein.

Abstract: A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin and callidinogenase. Lecithin derivatives are also disclosed.

Abstract: 11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the formula ##STR1## an antiinflammatory composition thereof and a method for the production thereof.11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the present invention exhibits remarkably excellent antiinflammatory action and besides, displays reduced side effects and can be produced in high selectivity and good yield and conveniently.

Abstract: An emulsion of lipid containing a prostaglandin analogue of the formula (1): ##STR1## wherein R.sup.1 is an alkanoyl group, R.sup.2 is a hydrogen atom or an alkyl group, each of R.sup.3 and R.sup.4 is a hydrogen atom or a protective group for an alcohol, R.sup.5 is an alkyl group which may have a substitutent, and is a single bond or a double bond.

Abstract: There is provided an ophthalmic preparation comprising a fat emulsion containing flurbiprofen or its derivative such as ester as an active ingredient.

Abstract: The fat emulsions containing the prostaglandin I.sub.2 's expressed by the following formula (I): ##STR1## where X represents an oxygen atom to a methine group, Y is a carbon atom, Z represents a methylene or methine group; when X is an oxygen atom, the mode of Y-Z binding is a double bond of carbon-carbon, and when X is a methine group, the mode of X-Y binding is a double bond of carbon-carbon and Z is a methylene group; R.sub.1 represents a hydrogen atom or alkyl group, R.sub.2 represents a hydrogen atom or fluorine atom, and R.sub.3 represents a hydrogen atom, methyl group, ethyl group or vinyl group. R.sub.4 represents a substituted or unsubstituted alkyl group with 1-10 carbon atoms, a substituted or unsubstituted alkenyl group with 2-10 carbons atoms, a substituted or unsubstituted alkynyl group with 2-10 carbon atoms, or a substituted or unsubstituted cycloalkyl group with 3-8 carbon atoms; and n is zero (0) or an integer of value 1.

Abstract: An emulsion of lipid containing a prostaglandin analogue of the formula (1): ##STR1## wherein R.sup.1 is an alkanoyl group, R.sup.2 is a hydrogen atom or an alkyl group, each of R.sup.3 and R.sup.4 is a hydrogen atom or a protective group for an alcohol, R.sup.5 is an alkyl group which may have a substituent, and is a single bond or a double bond.

Abstract: A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically-acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin, and callidinogenase. Lecithin derivatives are also disclosed.

Abstract: 11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the formula ##STR1## an antiinflammatory composition thereof and a method for the production thereof.11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the present invention exhibits remarkably excellent antiinflammatory action and besides, displays reduced side effects and can be produced in high selectivity and good yield and conveniently.

Abstract: A fat emulsion containing a prostaglandin E.sub.1 alkyl ester represented by the general formula ##STR1## wherein R denotes an alkyl group having 1 to 30 carbon atoms. The fat emulsion can be administered intravenously, has a long half-life of its effective ingredient, prostaglandin E.sub.1 alkyl ester, in the living body as well as a focus selectivity.

Abstract: A prostaglandin emulsion composition comprising a prostaglandin emulsified with a phosphatidylethanolamine-free phospholipid, the composition being suitable for intravenous administration.

Abstract: A pharmaceutical oil-in-water type micro-emulsion comprising fine particles of an oil or fat containing an effective amount of a 4-biphenylylacetic acid ester of the formula ##STR1## wherein R represents an alkyl group, an aqueous medium and a physiologically acceptable emulsifier for dispersing said fine particles in said aqueous medium.This micro-emulsion is useful for treating inflammation, pain and/or fever in a mammal.

Abstract: There is provided a fat emulsion of an ester of flurbiprofen having the formula ##STR1## wherein R is a group of the formula ##STR2## wherein R.sub.1 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, R.sub.2 is a C.sub.1 -C.sub.15 alkyl group or a C.sub.2 -C.sub.8 alkenyl group, and m is zero or an integer of 1; or a lactone group of the formula ##STR3## wherein R.sub.3 and R.sub.4 are same as or different from each other and are a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, and n is an integer of 1 or 2.The emulsion containing particles of a vegetable oil dissolving the ester can be orally or parenterally administered to human or animal for analgesia, antiphlogosis and antipyresis in various diseases and exhibits a high activity with small amounts in terms of flurbiprofen as compared with flurbiprofen itself.

Abstract: A fat emulsion for injection containing prostaglandin E.sub.1 which has a vasodilative action as well as a hypotensive action and a method for the production of such an emulsion. The present emulsion is effective in treating chronic arteriostenosis diseases.